Ibrutinib (PCI-32765)

目录号:S2680 中文名称:依鲁替尼

仅限科研使用

Ibrutinib (PCI-32765)是一种有效的,高选择性的Brutons tyrosine kinase (Btk)抑制剂,无细胞试验中IC50为0.5 nM,对Bmx, CSK, FGR, BRK及HCK适度有效,对EGFR, Yes, ErbB2, JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC

Ibrutinib (PCI-32765) Chemical Structure

CAS: 936563-96-1

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 2226.41 现货
RMB 1392.54 现货
RMB 7922.62 现货
RMB 20229.3 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Ibrutinib (PCI-32765)发表文献487篇:

产品安全说明书

Target Protein Ligand抑制剂选择性比较

生物活性

产品描述 Ibrutinib (PCI-32765)是一种有效的,高选择性的Brutons tyrosine kinase (Btk)抑制剂,无细胞试验中IC50为0.5 nM,对Bmx, CSK, FGR, BRK及HCK适度有效,对EGFR, Yes, ErbB2, JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC
靶点
BTK [1]
(Cell-free assay)
BLK [1]
(Cell-free assay)
Bmx [1]
(Cell-free assay)
CSK [1]
(Cell-free assay)
FGR [1]
(Cell-free assay)
点击更多
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
体外研究

Ibrutinib有效可逆且选择性抑制Btk酶活性。Ibrutinib作用于 BCR 通路激活的 DOHH2细胞系, 抑制Btk自磷酸化, Btk's 生理底物 PLCγ磷酸化, 和更远一点的下游激酶ERK的磷酸化,IC50分别为11 nM, 29 nM 和 13 nM。[1] Ibrutinib作用于慢性淋巴细胞白血病 (CLL) 细胞,诱导细胞毒性,这种作用存在剂量和时间依赖性。此外, Ibrutinib诱导 caspase依赖性细胞死亡通路激活,且在TLR信号后,抑制CLL细胞增殖能力。[2] 最新研究显示Ibrutinib抑制 BCR激活的原代 B细胞增殖,IC50 为8 nM,且抑制 原代单核细胞中TNFα, IL-1β 和 IL-6产量, IC50 分别为2.6 nM, 0.5 nM, 和 3.9 nM。 [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Rec1 cells NVm2TFhxTnWwY4Tpc44h[XO|YYm= Mm[wNk42KM7:TR?= M4HoOVYhcA>? M3\SeGlvcGmkaYTpc44hd2ZiTInuJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDS[YMyKGOnbHzzJIF1KDJwNTD1UUBqdmO3YnH0[YQh\m:{IE[gbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdibXX0bI9l MnW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkK4O|coRjJ3MkKyPFc4RC:jPh?=
human WSU-NHL cells NEfhPGNEgXSxdH;4bYPDqGG|c3H5 MorxO|IhcA>? NFvNS2xEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBYW1VvTljMJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNFkh|ryP M2PNWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
human SU-DHL6 cells NFrRZoxEgXSxdH;4bYPDqGG|c3H5 NWHJRlJZPzJiaB?= MoCxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3UuTEiONjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW4JO69VS5? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human DOHH2 cells NFTxRYZEgXSxdH;4bYPDqGG|c3H5 M{\4WVczKGh? MmTCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSG9JUDJiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MTFOwG0v NILzWG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 cells MYrGeY5kfGmxbjDhd5NigQ>? NEPwdXQyKGh? MV\Jcohq[mm2aX;uJI9nKEy\Tj3BJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYX\0[ZIhPjBibXnud{BjgSCWUj3GVmVVKEG|c3H5MEBKSzVyPUCuNkDPxE1w Mnj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
human Ramos cells MljTSpVv[3Srb36gZZN{[Xl? M1;2NVEhcA>? M{LtT2lvcGmkaYTpc44hd2ZiQoTrJIlvKGi3bXHuJHJidW:|IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWEyFLXfhcY1iOiCyaH;zdIhwenmuYYTpc44h[XRiVInyNVIyPyCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NF0yPCCwTT6= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human Pfeiffer cells NGfyc2pHfW6ldHnvckBie3OjeR?= MlL0O|IhcA>? MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQ[oVq\m[ncjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{IH7NMi=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 cells Mnn3SpVv[3Srb36gZZN{[Xl? NIjhboQyKGh? NXPsOmhJUW6qaXLpeIlwdiCxZjDoeY1idiCodXzsMYxmdme2aDDCWGsh\XiycnXzd4VlKGmwIGPmPUBk\WyuczD1d4lv\yCIQV2tV5JkfGmmZTDw[ZB1cWSnIHHzJJN2[nO2cnH0[UBi\nSncjC2NEBucW6|IHL5JHRTNU[URWSgRZN{[XoxvJygTWM2OD1yLkWgcm0v MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3OEW0O{c,OjF7NUi1OFc9N2F-
Sf9 insect cells NXjZTFg1TnWwY4Tpc44h[XO|YYm= NGf1S283OCCvaX7z MYDJR|UxKD1iMD6wNFA{KM7:TR?= MofhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
sf9 cells MoX0SpVv[3Srb36gZZN{[Xl? NX;yO4dDUUN3MDC9JFAvODByMzFOwG0> MnPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|YoRjJ5OUm0O|M3RC:jPh?=
Sf9 insect cells MmTUSpVv[3Srb36gZZN{[Xl? NE[5VVU3OCCvaX7z NIXkR3ZKSzVyIE2gNE4xODB|NDFOwG0> NXXVSVJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVIyPzVpPkK3PVEzOTd3PD;hQi=>
Sf9 insect cells NUSzU3ZLTnWwY4Tpc44h[XO|YYm= NISwdGg3OCCvaX7z M2jtW2lEPTBiPTCwMlAxODN2IN88US=> M17x[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOyPVQ3Lz5{OESzNlk1PjxxYU6=
Sf9 insect cells NHHVR25HfW6ldHnvckBie3OjeR?= MlrlOlAhdWmwcx?= MorTTWM2OCB;IECuNFAxOzRizszN M{CyZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
Sf9 cells M3PxVGZ2dmO2aX;uJIF{e2G7 Mly1OlAhdWmwcx?= NVTrNFR{UUN3MDC9JFAvODByNDFOwG0> NFfLdVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
Sf9 cells MUHGeY5kfGmxbjDhd5NigQ>? MXi2NEBucW6| NFntU5pKSzVyIE2gNE4xODB3IN88US=> NHTSNYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1PFU1Pyd-MkG5OVg2PDd:L3G+
Ramos cells M170W2Z2dmO2aX;uJIF{e2G7 NHq4cJMyKGh? M4LUNGlEPTBiPTCwMlAxODVizszN MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
Sf9 cells M33U[WZ2dmO2aX;uJIF{e2G7 NWfLeXhvPjBibXnudy=> MlmxTWM2OCB;IECuNFAyKM7:TR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
Pfeiffer cells MlfvR5l1d3SxeHnjbZR6KGG|c3H5 M3:zSVczKGh? MYfHTVUxKD1iMD6wNFIh|ryP NH3DfYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
B cells NEHjNndHfW6ldHnvckBie3OjeR?= NV3PcmZzOSCq NGPqfI5KSzVyIE2gNE4xODR4IN88US=> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ7MEm4PEc,OzB{OUC5PFg9N2F-
Sf9 insect cells M1zlRWZ2dmO2aX;uJIF{e2G7 NVXJVZBPOiC2bzC2NEBucW6| NHT1b|JMcSB;IECuNFA1QCEQvF2= NFfLTmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells M3Lnb2Z2dmO2aX;uJIF{e2G7 NGXUUFEyKGh? MnrjTWM2OCB;IECuNFA4PSEQvF2= M{jr[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
Sf9 insect cells MWHGeY5kfGmxbjDhd5NigQ>? NHeyc3g3OCCvaX7z M4LTRWlEPTBiPTCwMlAxQCEQvF2= Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
TMD8 cells MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NF3WTHU4OiCq Mli2TWM2OCB;IECuNFEh|ryP MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
CD19+ B cells Mmn0SpVv[3Srb36gZZN{[Xl? MmjrNUBp MkXGTWM2OCB;IECuNFEzKM7:TR?= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3N{m4Nkc,Ojl2NUe5PFI9N2F-
Sf9 insect cells MmnJSpVv[3Srb36gZZN{[Xl? M4rITlYxKG2rboO= MmrmTWM2OCB;IECuNFEzKM7:TR?= NF7OcW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells NXnRVYg3TnWwY4Tpc44h[XO|YYm= NIrxZWYyKGh? MWDJR|UxKD1iMD6wNVQh|ryP MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 insect cells NGnldIFHfW6ldHnvckBie3OjeR?= NFe3TpcyKGh? M{W5b2lEPTBiPTCwMlAyPDRizszN NXzlfIRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NVUxOjNpPkK5O|E2ODJ|PD;hQi=>
Sf9 insect cells MVTGeY5kfGmxbjDhd5NigQ>? NH7CcXQ3OCCvaX7z M3z0VGlEPTBiPTCwMlAyPjFizszN M2[wdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
HCC827 cells Mm\0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NWLiVY9YPzJiaB?= NHPkPHlKSzVyIE2gNE4xOzlizszN MnjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
PC9 cells MofzSpVv[3Srb36gZZN{[Xl? MWq3NkBp NW\xcZhlT0l3MDC9JFAvODVizszN NUXZcINyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
Sf9 cells M1:xSWZ2dmO2aX;uJIF{e2G7 MV[2NEBucW6| NHLnOnVKSzVyIE2gNE4yKM7:TR?= NWTPN49oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
H3255 cells NG\yeZVHfW6ldHnvckBie3OjeR?= MYW3NkBp NWDHXYRwT0l3MDC9JFAvOTFizszN NWW0dlRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BaF3 cells MVzGeY5kfGmxbjDhd5NigQ>? NIL0VZg4OiCq MX7HTVUxKD1iMD6xNkDPxE1? NGnYZ4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNFU2Oyd-Mk[2N|A2PTN:L3G+
BAF3 cells NH\acmJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= Ml\JO|IhcA>? Mmm4S2k2OCB;IECuNVIh|ryP MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
Sf9 insect cells NGS2fYZHfW6ldHnvckBie3OjeR?= NYrjRlVFPjBibXnudy=> M360XGlEPTBiPTCwMlEzOyEQvF2= NHruNYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Sf9 insect cells M2LCZmZ2dmO2aX;uJIF{e2G7 NYq5SppuPjBibXnudy=> NWjiT5JoUUN3MDC9JFAvOTR4IN88US=> NWjWd2F3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
BAF3 cells M17BRmZ2dmO2aX;uJIF{e2G7 NHXaWGc4OiCq NHPWVo5IUTVyIE2gNE4yPiEQvF2= M{HPN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
Sf9 cells NH7EXG5HfW6ldHnvckBie3OjeR?= NVPMUngyPjBibXnudy=> MnfMTWM2OCB;IECuNkDPxE1? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3OEW0O{c,OjF7NUi1OFc9N2F-
MV411 cells MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4HFWmdKPTBiPTCwMlI2KM7:TR?= NGPD[IQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
MV4-11 cells NWjy[XM5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MoDNO|IhcA>? MoDHS2k2OCB;IECuN|Mh|ryP NUn3dYlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N|A2PTNpPkK2OlMxPTV|PD;hQi=>
MV4-11 cells M3ruTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NX:5ZmlGPzJiaB?= NELJTIdIUTVyIE2gNE4{OyEQvF2= M1rvdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
DOHH2 cells MnL6R5l1d3SxeHnjbZR6KGG|c3H5 M37DdFczKGh? M3nPZWdKPTBiPTCwMlQyKM7:TR?= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
HCC827 cells NVK3NHo{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M3W2dFk3KGh? M2rLbWVEPTBiPTCwMlQ2KM7:TR?= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
SU-DHL6 cells NFju[XBEgXSxdH;4bYNqfHliYYPzZZk> Mn\tO|IhcA>? M4PKXWdKPTBiPTCwMlU5KM7:TR?= M3zINVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
M07e cells NWfQ[Wx[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4nQXGdKPTBiPTCwMlU6KM7:TR?= M1eyPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
NCI-H1975 cells NVnMNpp4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MV25OkBp NVPGW|g2TUN3MDC9JFAvPjRizszN NITnXGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
SU-DHL-2 cells MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEXoWWFIUTVyIE2gNE43PCEQvF2= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
HEK293T cells MUjGeY5kfGmxbjDhd5NigQ>? MX[xJIg> M4\PUWlEPTBiPTCwMlkh|ryP MnnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
Ramos cells M{H4Z2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NETPNJU4OiCq NEnLSpJKSzVyIE2gNE46OiEQvF2= M13wXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
BA/F3 cells Ml7URY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MVi3NkBp MkXkTWM2OCB;IEGg{txO NHH5U2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
WSU-NHL cells NU\hbW51S3m2b4TvfIlkcXS7IHHzd4F6 Mor0O|IhcA>? MlXFS2k2OCB;IEGuNFkh|ryP NYTsbZpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
NCI-H1975 cells MnnzSpVv[3Srb36gZZN{[Xl? MnfyO|IhcA>? M2LwW2dKPTBiPTCxMlIh|ryP MoXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975 cells MmH6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NWTSd41OPzJiaB?= MmXiTWM2OCB;IEGuNlch|ryP NYnrS21XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N|Q2QDFpPkK4O|M1PThzPD;hQi=>
Raji cells NGrBcFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NU\yXIFxPDhiaB?= NVO0bGFSUUN3MDC9JFEvPDlizszN NGn2Wms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW2O|I6PSd-Mkm1OlczQTV:L3G+
Pfeiffer cells MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWrGe2trT0l3MDC9JFEvPiEQvF2= MlnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
A431 cells NGf6S3NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MmrNPVYhcA>? MYPFR|UxKD1iMj6zPEDPxE1? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
BAF3 cells M1P5WGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MU[3NkBp NHPaZodIUTVyIE2gNk42KM7:TR?= M2S3NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
U937 cells M1m4Umdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYDSNFMxT0l3MDC9JFIvQSEQvF2= NHjje3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
NB4 cells MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIPoc2hIUTVyIE2gN{DPxE1? NVHaVoE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
Ramos cells NUTuToFVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIPEZ2VIUTVyIE2gN{41KM7:TR?= NVryN4poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
SKM1 cells MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGPhO4NIUTVyIE2gN{43KM7:TR?= NH\LeJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
U2932 cells MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEDoOJZIUTVyIE2gOE41KM7:TR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Ramos cells M3vXWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MVy3NkBp M13kTGlEPTBiPTC1MlE1KM7:TR?= M1SyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC2NVQ{Lz5|MECwOlE1OzxxYU6=
Ramos cells MnOxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NYLieVVTPDhiaB?= MUDJR|UxKD1iNT6xOEDPxE1? NXHtXItlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
Ramos cells MlG5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NUjDT|ZWPDhiaB?= NH7JPZZKSzVyIE2gOU45QCEQvF2= M1;EW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOyPVQ3Lz5{OESzNlk1PjxxYU6=
Ramos cells NGrhbYZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MU[3NkBp MnLuTWM2OCB;IE[uOlIh|ryP MmrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
K562 cells NXXXR|dySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NGq4cXA1QCCq MnX6TWM2OCB;IEeuOUDPxE1? NWDxdY1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO|c3ODhpPkOwNFc4PjB6PD;hQi=>
HL60 cells M4n5UmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MUG0PEBp MmGzTWM2OCB;IEig{txO M2H4WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5|MEC3O|YxQDxxYU6=
Ramos cells NInHXIhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NGP5PW01QCCq MkDCTWM2OCB;IEiuNVEh|ryP M13k[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M3Lz5{N{m5OFc{PjxxYU6=
Ramos cells NV3rRlhZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MkHnOFghcA>? NFi5V4lKSzVyIE2gPE4zPiEQvF2= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV4N{K5OUc,Ojl3NkeyPVU9N2F-
OCI-AML3 cells NVy0[Yx4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV\HTVUxKD1iOT6yJO69VQ>? NXXae2ZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
BAF3 cells NXvuU3ViS3m2b4TvfIlkcXS7IHHzd4F6 NXi0VVl3PzJiaB?= MoTNS2k2OCB;IEGwJO69VQ>? NFPEUXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNFU2Oyd-Mk[2N|A2PTN:L3G+
BAF3 cells M{f2cGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NE\UNlk4OiCq MUnHTVUxKD1iMUCg{txO NXu4S5c6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ|PD;hQi=>
BAF3 cells NXX0[Wk6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1rRbVczKGh? MnXGS2k2OCB;IEGwJO69VQ>? NHj6W3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NAMALWA cells MmrCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M3m3dVczKGh? NVTkbXltUUN3MDC9JFExNjR3IN88US=> MlrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
Ramos cells MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NW\JV5U1PDhiaB?= Mo\OTWM2OCB;IEGyMlYh|ryP NULoTlFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVIyPzVpPkK3PVEzOTd3PD;hQi=>
Raji cells NW\VVm5HSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M12wbFQ5KGh? M{TnR2lEPTBiPTCxOE4zKM7:TR?= NYLRZVR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO|c3ODhpPkOwNFc4PjB6PD;hQi=>
Raji cells NETybGNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MWi0PEBp NVi4ZlZKUUN3MDC9JFE2NjJizszN MkTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|YoRjJ5OUm0O|M3RC:jPh?=
MIAPaCa2 cells MYjDfZRwfG:6aXPpeJkh[XO|YYm= MXizJIRigXN? NGfxdmpKSzVyIE2gNVYvPiEQvF2= M{LQclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEe3NlI5Lz5{N{C3O|IzQDxxYU6=
HeLa cells MV3DfZRwfG:6aXPpeJkh[XO|YYm= M1HNWVMh\GG7cx?= M1SxWWlEPTBiPTCxOk45KM7:TR?= MnvJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyN{eyNlgoRjJ5MEe3NlI5RC:jPh?=
Raji cells NVn5Z|Q{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NYrnSWNXPDhiaB?= NIHXTIZKSzVyIE2gNVkvOyEQvF2= NV\6UGw3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVIyPzVpPkK3PVEzOTd3PD;hQi=>
Raji cells MlnTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NUXjWm02PDhiaB?= MlLrTWM2OCB;IEG5MlMh|ryP MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|Mkm0Okc,Ojh2M{K5OFY9N2F-
Raji cells MoS1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? Mo\zO|IhcA>? M4PwOmlEPTBiPTCxPU42KM7:TR?= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
Raji cells MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NVPnU|kxPDhiaB?= NFXz[IpKSzVyIE2gNVkvPSEQvF2= M{TEW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
NAMALWA cells NHHme2lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M{X1d|czKGh? NVO3VHp4UUN3MDC9JFE6NjZizszN NIDGbmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
A2780 cells M3jndWN6fG:2b4jpZ4l1gSCjc4PhfS=> NXHVflJiOyCmYYnz MWDFR|UxKD1iMkCuNUDPxE1? NXzqU3hMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
Raji cells MnHwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NFTz[|E4OiCq NETwOY1KSzVyIE2gNlAvQDhizszN NX;idWo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFYyOzZpPkK5NVQ3OTN4PD;hQi=>
A549 cells M3jMUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NVfsTYxTPzJiaB?= M3;MRmlEPTBiPTCyNU44QSEQvF2= NI\JWo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEezOFU5OSd-Mki3N|Q2QDF:L3G+
SW480 cells Mk[xR5l1d3SxeHnjbZR6KGG|c3H5 MmLIN{Bl[Xm| MVXJR|UxKD1iMkWuOkDPxE1? MnXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyN{eyNlgoRjJ5MEe3NlI5RC:jPh?=
Ramos cells NWLYSG94S3m2b4TvfIlkcXS7IHHzd4F6 MUOyOEBp NVLBSIVGUUN3MDC9JFI5NjdizszN MkfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{N{S2O|UoRjJ6Mke0Olc2RC:jPh?=
Assay
Methods Test Index PMID
Western blot pEGFR(Tyr1068) / EGFR pBTK / pPLCγ2 / pAKT / pERK / pJNK 28061447 23940282
Immunofluorescence CD11b COX-2 30231870
ELISA hTNFα IL-10 26627823 27792904
体内研究

Ibrutinib 作用于胶原诱导的关节炎模型,通过抑制B细胞活性,显著降低足肿胀和关节发炎等临床关节炎症状。Ibrutinib 作用于 MRL-Fas(lpr) 狼疮模型 ,降低肾疾病和自身抗体产量。[1] Ibrutinib 每天按25 mg/kg剂量作用于过继转移TCL1 的CLL小鼠模型, 产生短暂的早期淋巴细胞增多症,且延迟CLL 疾病进展。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

  • 激酶实验:

    激酶, 33P-ATP, Ibrutinib, 和底物 [0.2 mg/mL 聚(EY)(4:1)]温育1小时后,使用33P 过滤结合实验测量体外激酶IC50值。

细胞实验:

[2]

  • Cell lines: 慢性淋巴细胞白血病 (CLL) 细胞
  • Concentrations: 0.01 μM到100 μM
  • Incubation Time: 48小时
  • Method:

    进行MTT实验测定细胞毒性。细胞(CLL B 细胞或健康志愿者T 细胞或 NK细胞) 和不同浓度 Ibrutinib温育48小时。加入MTT试剂,实验板再温育20小时,然后使用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO,通过分光光度法使用Labsystems 酶标仪,在540 nm处测定吸光值。使用膜联蛋白/PI 流式细胞仪在不同时间点测量细胞活力。使用 Expo-ADC32 软件包分析数据。结果表示为总阳性细胞与对照组之比的百分数。加入100μM Z-VAD检测caspase依赖性凋亡。

动物实验:

[1]

  • Animal Models: MRL-Fas(lpr) 狼疮模型和胶原诱导的关节炎模型
  • Dosages: ≤50 mg/kg
  • Administration: 口服处理

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+5% Tween 80+ddH2O

10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 440.5
化学式

C25H24N6O2

CAS号 936563-96-1
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04665115 Withdrawn Drug: Ibrutinib|Other: Quality-of-Life Assessment Asymptomatic COVID-19 Infection Laboratory-Confirmed|B-Cell Neoplasm|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Symptomatic COVID-19 Infection Laboratory-Confirmed|Waldenstrom Macroglobulinemia Academic and Community Cancer Research United|National Cancer Institute (NCI) December 2021 Phase 2
NCT05105841 Recruiting Drug: Venetoclax|Drug: Ibrutinib|Drug: Obinutuzumab Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL) AbbVie November 8 2021 Phase 2
NCT04876092 Recruiting Drug: JNJ-67856633|Drug: Ibrutinib Leukemia Lymphocytic Chronic B-Cell|Lymphoma Non-Hodgkin Janssen Research & Development LLC July 28 2021 Phase 1
NCT04294641 Recruiting Drug: Ibrutinib Chronic GVHD National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 10 2021 Phase 2
NCT05429918 Recruiting -- Mantle Cell Lymphoma Peking University Third Hospital|The Second Affiliated Hospital of Dalian Medical University|Peking University First Hospital|Beijing Hospital|Beijing Tsinghua Changgeng Hospital|China-Japan Friendship Hospital|Chinese PLA General Hospital|First Affiliated Hospital of Harbin Medical University|Baotou Cancer Hospital|Beijing Shijitan Hospital Capital Medical University|Shanxi Province Cancer Hospital|Beijing Naval General Hospital|First Hospital of China Medical University|Jilin Provincial Tumor Hospital|Shengjing Hospital|307 Hospital of PLA|Peking Union Medical College Hospital|Harbin Medical University|Beijing Tongren Hospital December 30 2020 --
NCT05406154 Recruiting -- Mantle Cell Lymphoma (MCL) Peking University Third Hospital|Peking Union Medical College Hospital|The Second Affiliated Hospital of Dalian Medical University|Peking University First Hospital|Beijing Tongren Hospital|Beijing Hospital|Beijing Tsinghua Changgeng Hospital|China-Japan Friendship Hospital|307 Hospital of PLA|Chinese PLA General Hospital|First Affiliated Hospital of Harbin Medical University|Harbin Medical University|Baotou Cancer Hospital|Beijing Shijitan Hospital Capital Medical University|Shanxi Province Cancer Hospital|Beijing Naval General Hospital|First Hospital of China Medical University|Jilin Provincial Tumor Hospital|Shengjing Hospital December 30 2020 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
How to reconstitute the compound S2680 for in vivo studies?

回答:
For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Tags: buy Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765) supplier | purchase Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765) cost | Ibrutinib (PCI-32765) manufacturer | order Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765) distributor